Recently, advances in cancer neuroscience have highlighted neurotrophins—nerve growth factor (NGF) and brain−derived neurotrophic factor (BDNF)—and their Trk/p75NTR receptors as modulators of tumor behavior and immune tone, offering a new strategy to recondition the osteosarcoma microenvironment. This evidence concerns the gene BDNF and osteosarcoma.